• J-P Lin, Y-J Zhao, Q-L He, H-K Hao, Y-T Tian, B-B Zou, L-X Jiang, W Lin, Y B Zhou, Z Li, Y-C Xu, G Zhao, F-Q Xue, S-L Li, W-H Fu, Y-X Li, X-J Zhou, Y Li, Z-G Zhu, J-P Chen, Z-K Xu, L-H Cai, E Li, H-L Li, J-W Xie, C-M Huang, P Li, J-X Lin, and C-H Zheng.
• Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
• Br J Surg. 2020 Aug 1; 107 (9): 1163-1170.

BackgroundThe aim of this study was to evaluate whether adjuvant chemotherapy is associated with improved survival in patients with resectable gastric neuroendocrine carcinomas (G-NECs) or mixed adenoneuroendocrine carcinomas (G-MANECs).MethodsThe study included patients with G-NECs or G-MANECs who underwent surgery in one of 21 centres in China between 2004 and 2016. Propensity score matching analysis was used to reduce selection bias, and overall survival (OS) in different treatment groups was estimated by the Kaplan-Meier method.ResultsIn total, 804 patients with resectable G-NECs or G-MANECs were included, of whom 490 (60·9 per cent) received adjuvant chemotherapy. After propensity score matching, OS in the chemotherapy group was similar to that in the no-chemotherapy group. Among patients with G-NECs, survival in the fluorouracil (5-FU)-based chemotherapy group and the non-5-FU-based chemotherapy group was similar to that in the no-chemotherapy group. Similarly, etoposide plus cisplatin or irinotecan plus cisplatin was not associated with better OS in patients with G-NECs. Among patients with G-MANECs, OS in the non-5-FU-based chemotherapy group was worse than that in the no-chemotherapy group. Patients with G-MANECs did not have better OS when platinum-based chemotherapy was used.ConclusionThere was no survival benefit in patients who received adjuvant chemotherapy for G-NECs or G-MANECs.© 2020 BJS Society Ltd Published by John Wiley & Sons Ltd.

36 keywords...

hide…